Second Sight Medical Products, Inc (EYES)

US stock futures traded higher on Thursday, with the Dow futures adding more than 200 points this morning. Investors, meanwhile, ...

The directors of a company tend to have a unique inside view into the business, so when directors make major buys, investors are wise to take notice. Presumably the only reason a director of a company would choose to take their hard-earned cash and use it to buy stock in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both..

Investors in Second Sight Medical Products Inc (EYES) saw new options become available this week, for the November 18th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 204 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight”), a recognized global leader in neuromodulation devices for blindness, today announced that an interview with Adam Mendelsohn, Ph.D., Co-Founder and CEO of Nano Precision Medical, Inc. (“NPM”), will air on The RedChip Money Report® on Bloomberg US on April 16 at 7 p.m. Eastern Time (ET). Bloomberg US is available in an estimated 73 million homes across the United States.

Halper Sadeh LLP, an investor rights law firm, is investigating whether the merger of Second Sight Medical Products, Inc. (NASDAQ: EYES) and Nano Precision Medical, Inc. is fair to Second Sight shareholders.

Gainers Society Pass Incorporated(NASDAQ: SOPA) shares climbed 42.7% to close at $4.68 on Tuesday after dropping ...

Gainers Society Pass Incorporated (NASDAQ: SOPA) gained 63.4% to $3.45 after dropping 16% on Monday. American Rebel Holdings, ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips EYES stock is up 15% today on news that Second Sight Medical is making a strategic acquisition. Here's what to know. The post EYES Stock Pops on Biotech Merger Plans. 5 Things to Know. appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

Gainers Second Sight Medical (NASDAQ:EYES) stock increased by 7.8% to $1.51 during Tuesday's pre-market session. The ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! We've got another busy day ahead of us so let's get right into it with the biggest pre-market stock movers for Tuesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

Second Sight Medical Products Inc(NASDAQ: EYES) will acquire privately-heldNano Precision Medical Incin an all-stock ...

Gainers American Rebel Holdings, Inc.(NASDAQ: AREB) rose 142% to $5.35 in pre-market trading following uplisting ...

Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”) and Nano Precision Medical, Inc. (“NPM”), today announced that they have entered into a definitive agreement under which privately held NPM will merge with a wholly owned subsidiary of Second Sight in an all-stock transaction. NPM will be the surviving company and owned by Second Sight. The resulting company will focus on development of innovative drug and device medical implants that treat chronic diseases with high unmet medical need.

Gainers Sono Group N.V. (NASDAQ: SEV) shares climbed 154.7% to close at $38.20 on Wednesday after the company priced its IPO at ...

Gainers EyePoint Pharmaceuticals (NASDAQ:EYPT) shares moved upwards by 25.83% to $17.68 during Wednesday's regular session. The ...

Gainers Sono Group N.V. (NASDAQ: SEV) shares jumped 66% to $24.90 after the company priced its IPO at $15 per share. EyePoint ...

Gainers Rockwell Medical (NASDAQ:RMTI) shares rose 47.27% to $0.71 during Wednesday's pre-market session. The ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! We're halfway through the week and with that comes a look at the biggest pre-market stock movers for Wednesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

Gainers 17 Education & Technology Group Inc. (NASDAQ: YQ) rose 283.5% to $3.16 in pre-market trading. 17 Education & ...

Gainers BIMI International Medical Inc. (NASDAQ: BIMI) shares surged 55% to close at $1.00 on Tuesday as the company reported a ...

Investors in Second Sight Medical Products Inc (EYES) saw new options begin trading this week, for the January 2024 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 802 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Gainers T2 Biosystems (NASDAQ:TTOO) shares increased by 23.47% to $1.02 during Thursday's after-market session. T2 Biosystems's ...

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announces that the Company received a grant supplement from the National Institutes of Health (NIH) to fund a qualitative study to gather critical insights into how profoundly blind people weigh the risks and benefits of visual neuroprostheses. The study will help the Company better understand acceptable risks, necessary benefits, and appropriate risk/benefit balance for visual cortical prostheses, from the perspective of the target population. The entirety of the $155,964 grant supplement will be provided to UCLA as a subcontractor to conduct the study. The grant supplement is related to the $6.4 million NIH grant for the Early Feasibility Clinical Trial of a Visual Cortical Prosthesis, grant UH3NS103442. Second Sight reported promising two-year data from the Orion trial on May 12, 2021.

Gainers NanoVibronix (NASDAQ:NAOV) shares rose 21.45% to $3.17 during Friday's after-market session. This security traded at a ...